Navigation Links
Escalon(R) Medical Corp. Completes Bolt-On Acquisition, Enhances Market Position in France and Expands Product Offering
Date:1/6/2009

ACQUIRES HEMATOLOGY BUSINESS ASSETS FROM BIOCODE HYCEL

WAYNE, Pa., Jan. 6 /PRNewswire-FirstCall/ -- Escalon Medical Corp. (Nasdaq Capital Market: ESMC) announced that on December 31, 2008 pursuant to an Asset Purchase Agreement it completed the previously announced acquisition of the hematology business of Biocode Hycel, the French subsidiary of Immunodiagnostic Systems plc, a provider of in vitro diagnostic products. The acquired hematology business will continue to operate under the name Biocode Hycel and has operations near Rennes, France. The acquired hematology business had 2008 annual revenues of approximately Euro 4,200,000, or approximately $5,800,000. The business will be vertically integrated into Escalon's clinical diagnostics business and its growing portfolio of brands, which also includes Drew Scientific and JAS Diagnostics.

The purchase price for the acquisition was Euro 4,200,000, of which Euro 25,000 was paid upfront. The seller-provided financing requires payment over four years as follows:

  • the first interest-only payment is due in December of 2009;
  • thereafter, every six months, an interest payment is due at an annual interest rate of 7%;
  • after 18 months a principal payment of Euro 800,000 is due;
  • after 30 months a principal payment of Euro 1,000,000 is due;
  • after 36 months a principal payment of Euro 1,000,000 is due; and
  • after 48 months a principal payment of Euro 1,375,000 is due.

The payment amount in United States Dollars will be determined on the payment due date, based upon the then current exchange rate between the United States Dollar and the Euro.

Strong Strategic Fit for Drew

Richard J. DePiano, Jr. President, commented, "This acquisition of hematology assets from Biocode Hycel is a natural extension of Drew's business model and provides an immediate and significant presence in the French diagnostic market. Furthermore, the addition of proprietary hematology equipment, technology, and reagent formulas strategically broadens Drew's well recognized product offering and enhances our strategy to leverage cross-selling and revenue growth opportunities."

Founded in 1987, the Company (http://www.escalonmed.com) develops markets and distributes ophthalmic diagnostic, surgical and pharmaceutical products as well as vascular access devices. Drew Scientific, which operates as a separate business unit, provides instrumentation and consumables for the diagnosis and monitoring of medical disorders in the areas of diabetes, cardiovascular diseases and hematology, as well as veterinary hematology and blood chemistry. The Company seeks to utilize strategic partnerships to help finance its development programs and is also seeking acquisitions to further diversify its product line to achieve critical mass in sales and take better advantage of the Company's distribution capabilities, although such partnerships or acquisitions may not occur. The Company has headquarters in Wayne, Pennsylvania and operations in Long Island, New York, New Berlin, Wisconsin, Lawrence, Massachusetts, Dallas, Texas, Waterbury, Connecticut, Miami, Florida, Barrow-in-Furness, U.K. and Le Rheu, France.

Note: This press release contains statements that are considered forward-looking under the Private Securities Litigation Reform Act of 1995, including statements about the Company's future prospects. These statements are based on the Company's current expectations and are subject to a number of uncertainties and risks, and actual results may differ materially. The uncertainties and risks include whether the Company is able to:

  • implement its growth and marketing strategies, improve upon the operations of the Company business units, including the ability to make acquisitions and the integration of any acquisitions it may undertake, if any, of which there can be no assurance,
  • implement cost reductions,
  • generate cash,
  • identify, finance and enter into business relationships and acquisitions, and make timely payments for any financing, and
  • new product development, commercialization, manufacturing and market acceptance of new products.

Other factors include uncertainties and risks related to:

  • marketing acceptance of existing products in new markets,
  • research and development activities, including failure to demonstrate clinical efficacy,
  • delays by regulatory authorities, scientific and technical advances by the Company or third parties,
  • introduction of competitive products,
  • ability to reduce staffing and other costs and retain benefit of prior reductions
  • third party reimbursement and physician training, and
  • general economic conditions.

Further information about these and other relevant risks and uncertainties may be found in the Company's reports on Form 10-K for year ended June 30, 2008 and Form 10-Q for the quarter ended September 30, 2008, and its other filings with the Securities and Exchange Commission, all of which are available from the Securities and Exchange Commission as well as other sources.


'/>"/>
SOURCE Escalon Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Escalon(R) Reports Financial Results for 2007 Fiscal Year
2. Escalon(R) Reports First Quarter Fiscal 2008 Results
3. Escalon(R) Announces FDA 510(K) Clearance for D3 Hematology System
4. Escalon(R) Announces Executive Promotions
5. Escalon(R) Announces China Registration for Sonomed PacScan(R) and E/Z-Scan(R) Series of A-scan, Pachymeter and B-Scan Systems
6. Escalon(R) Enhances Position Within IVD Reagent Market with Strategic Acquisition of JAS Diagnostics
7. Escalon(R) Receives FDA 510(k) Clearance to Market the LIASYS(TM) Clinical Chemistry and Immunoturbidimetric Analyzer
8. Escalon(R) Reports First Quarter Fiscal 2009 Results
9. Escalon(R) Medical Corp. Completes $1.1 Million Private Equity Financing
10. MSU engineering team designs innovative medical device
11. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... May 26, 2017 , ... Somnoware, a ... portable sleep monitor with its Somnoware Sleep Device Interface (SDI). Somnoware SDI is ... device operations. With this platform, initializing devices and importing studies are just one-click ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... On May ... (AHCA), which narrowly passed the U.S. House on May 4, would result in 23 ... expected under continued implementation of the 2010 Patient Protection and Affordable Care Act (ACA). ...
(Date:5/26/2017)... ... May 26, 2017 , ... Rob Lowe acts as host and helps educate ... is on hiking in American. Viewers can reconnect with America as it explores some ... , Many consumers have looked for an inventive new place for a family vacation, ...
(Date:5/26/2017)... Centennial, Colorado (PRWEB) , ... May 26, 2017 ... ... Exchange will be this year’s recipient of proceeds from its 14th Annual Clays ... Club, 46700 E. County Road 30, Bennett, Colorado. , As part of ...
(Date:5/24/2017)... ... May 24, 2017 , ... Last ... Mary Ellen, hospital employees, and town officials to celebrate the grand opening of ... developed by Rendina as part of its ongoing relationship with RWJBarnabas Health, New ...
Breaking Medicine News(10 mins):
(Date:5/8/2017)... YORK , May 8, 2017 ... the transition from fee for service reimbursement. Black Book ... 2017. 1.       The Market for MIPS ... 77% of physician practices with 3 or more ... Technology Solutions by Q4. "Given the magnitude of the ...
(Date:5/6/2017)... 5, 2017  Hill-Rom Holdings, Inc. (NYSE: HRC), has ... square feet to its Welch Allyn campus. ... to bring more than 100 new jobs to ... has maintained a significant presence for more than 100 ... positions, a large portion of which will be R&D ...
(Date:5/4/2017)... SAN DIEGO , May 4, 2017  The ... Clinical and Scientific Meeting— OBP Medical , a leading ... announced the launch of a new extra-small size and ... ER-SPEC vaginal specula. Already available in small, ... sizes makes OBP Medical,s line of single-use lighted specula ...
Breaking Medicine Technology: